Keya Medical hosted a sponsored webinar at SCCT 2026 featuring experts in cardiac CT discussing CCTA evolution beyond anatomical stenosis assessment.

Public source

Publisher name

Public post

Beyond stenosis: bringing anatomy, plaque, and physiology together in CCTA How can quantitative plaque analysis and CT-FFR work together to provide a more comprehensive…

Log in to read the full post

Company

Keya Medical

AI for Smarter Healthcare

Industry
Medical Device
Location
Seattle, US
Company size
11–50 employees

About Keya Medical

Keya Medical is an international medical technology company developing deep learning-based solutions that support disease diagnosis and treatment. Our CCTA portfolio includes two FDA-cleared software medical devices: DEEPVESSEL FFR, which provides noninvasive physiological assessment of the coronary arteries, and DEEPVESSEL Plaque, which quantifies coronary plaque and stenosis. Together, they provide complementary functional and anatomical insights to support the assessment and management of coronary artery disease. DEEPVESSEL FFR is also CE-marked and NMPA-approved.

See more

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.